diallylcyanamide | 693-50-5

• 分子结构分类: 有机化合物 - 有机氮化合物
• 英文名称: diallylcyanamide
• 英文别名: diallyl-carbodiimide；Diallyl-carbodiimid；Diallylcarbodiimid；N,N'-bis(allyl)carbodiimide
• CAS: 693-50-5
• 化学式: C₇H₁₀N₂
• 分子量: 122.17
• InChiKey: JKOPIMHCDFWZHJ-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.7
• 重原子数：
  9
• 可旋转键数：
  4
• 环数：
  0.0
• sp3杂化的碳原子比例：
  0.29
• 拓扑面积：
  24.7
• 氢给体数：
  0
• 氢受体数：
  2

反应信息

• 作为反应物：
  描述：

  diallylcyanamide 在 platinum(IV) oxide 氢气 作用下， 以 乙醚 、 乙醇 为溶剂， 25.0 ℃ 、101.33 kPa 条件下， 反应 4.0h， 生成 1,3-dipropylthymine
  参考文献：
  名称：

  N，N'-用2-（溴甲基）丙烯酸环化碳二亚胺。直接进入系统5-亚甲基-6 H-嘧啶-2,4-二酮，一类新型的胸腺嘧啶类似物

  摘要：

  碳二亚胺在非常温和的条件下在两个N原子处与2-（溴甲基）丙烯酸反应，以中等至良好的产率得到1,3-二取代的-5-亚甲基-6 H-嘧啶2,4-二酮衍生物。这些产品对各种亲核试剂（如溴，盐酸，氢化物等）表现出良好的迈克尔受体作用。基于理论方法和实验结果，提出了一种合理的机制。

  DOI：

  10.1002/jhet.5570330444
• 作为产物：
  描述：

  1,3-二烯丙基-2-硫脲 在 乙醚 、 mercury(II) oxide 作用下， 生成 diallylcyanamide
  参考文献：
  名称：

  Schmidt; Hitzler; Lahde, Chemische Berichte, 1938, vol. 71, p. 1933,1936

  摘要：

  DOI：

文献信息

• [EN] SUBSTITUTED 5-,6- AND 7-MEMBERED HETEROCYCLES, MEDICAMENTS CONTAINING SUCH COMPOUNDS, AND THEIR USE<br/>[FR] HÉTÉROCYCLES À 5, 6 ET 7 CHAÎNONS SUBSTITUÉS, MÉDICAMENTS CONTENANT CES COMPOSÉS ET LEUR UTILISATION
  申请人：VITAE PHARMACEUTICALS INC

  公开号：WO2011159760A1

  公开（公告）日：2011-12-22

  The present invention relates to compounds defined by formula I: wherein the variables A1, A2, Cy1 Cy2, Cy3, E, R1a, R1b, R2, R3, n, and Q are as defined herein, possessing valuable pharmacological activity. Particularly, the compounds are inhibitors of 11 β-hydroxysteroid dehydrogenase (HSD) 1 and thus are suitable for treatment and prevention of diseases which can be influenced by inhibition of this enzyme, such as metabolic diseases, in particular diabetes type 2, obesity, and dyslipidemia.

  本发明涉及由以下式I定义的化合物：其中变量A1、A2、Cy1、Cy2、Cy3、E、R1a、R1b、R2、R3、n和Q如本文所定义，具有有价值的药理活性。特别地，这些化合物是11β-羟基类固醇脱氢酶（HSD）1的抑制剂，因此适用于治疗和预防可以受到该酶抑制影响的疾病，如代谢性疾病，特别是2型糖尿病、肥胖症和血脂异常。
• NOVEL PROCESSES FOR THE PREPARATION OF PHENYLCYCLOPROPYLAMINE DERIVATIVES AND USE THEREOF FOR PREPARING TICAGRELOR
  申请人：Khile Anil Shahaji

  公开号：US20130165696A1

  公开（公告）日：2013-06-27

  Provided herein are novel processes for the preparation of phenylcyclopropylamine derivatives, which are useful intermediates in the preparation of triazolo[4,5-d]pyrimidine compounds. Provided particularly herein are novel, commercially viable and industrially advantageous processes for the preparation of a substantially pure ticagrelor intermediate, trans-(1R,2S)-2-(3,4-difluorophenyl)-cyclopropylamine. Provided further herein are novel acid addition salts of trans-(1R,2S)-2-(3,4-difluorophenyl)-cyclopropylamine, and process for their preparation. The intermediate and its acid addition salts are useful for preparing ticagrelor, or a pharmaceutically acceptable salt thereof, in high yield and purity.

  本文提供了一种制备苯基环丙胺衍生物的新型工艺，这些衍生物在三唑并[4,5-d]嘧啶化合物的制备中是有用的中间体。特别提供了一种新颖、商业可行且在工业上具有优势的工艺，用于制备一种基本纯的替卡格雷中间体，即trans-(1R,2S)-2-(3,4-二氟苯基)-环丙胺。此外，本文还提供了trans-(1R,2S)-2-(3,4-二氟苯基)-环丙胺的新型酸加盐，以及其制备工艺。该中间体及其酸加盐对于高产率和纯度制备替卡格雷或其药用可接受盐是有用的。
• New 7,8-dihydro-1,6-naphthyridin-5(6h)-one-derivatives as PDE4 inhibitors
  申请人：Almirall, S.A.

  公开号：EP2380890A1

  公开（公告）日：2011-10-26

  New 7,8-dihydro-1,6-naphthyridin-5(6H)-one derivatives derivatives having the chemical structure of formula (I) are disclosed; as well as process for their preparation, pharmaceutical compositions comprising them and their use in therapy as inhibitors of the phosphodiesterase IV (PDE4).

  揭示了具有化学结构式（I）的新的7,8-二氢-1,6-萘啶-5(6H)-酮衍生物衍生物；以及它们的制备方法，包含它们的药物组合物以及它们作为磷酸二酯酶IV（PDE4）抑制剂在治疗中的用途。
• Alicyclic carboxylic acid derivatives of benzomorphans and related scaffolds, medicaments containing such compounds and their use
  申请人：Peters Stefan

  公开号：US20110269791A1

  公开（公告）日：2011-11-03

  The present invention relates to compounds defined by Formula (I), wherein the groups A, B, X, m, n and o are defined as in claim 1, possessing valuable pharmacological activity. Particularly the compounds are inhibitors of 11β-hydroxysteroid dehydrogenase (HSD) 1 and thus are suitable for treatment and prevention of diseases which can be influenced by inhibition of this enzyme, such as metabolic diseases, in particular diabetes type 2, obesity and dyslipidemia.

  本发明涉及由式（I）定义的化合物，其中A、B、X、m、n和o基团的定义如权利要求1中所述，具有有价值的药理活性。特别是这些化合物是11β-羟基类固醇脱氢酶（HSD）1的抑制剂，因此适用于治疗和预防可以受到该酶抑制影响的疾病，如代谢性疾病，特别是2型糖尿病、肥胖症和血脂异常。
• [EN] NEW EFFICIENT METHODS FOR THE SYNTHESIS OF TAXANE DERIVATIVES SUCH AS DOCETAXEL AND THEIR STRUCTURAL ANALOGOUS, AND A METHOD FOR THE PREPARATION THEREOF<br/>[FR] NOUVEAUX PROCÉDÉS EFFICACES POUR LA SYNTHÈSE DE DÉRIVÉS DE TYPE TAXANE TELS QUE LE DOCÉTAXEL ET LEURS ANALOGUES STRUCTURAUX, ET PROCÉDÉ DE PRÉPARATION DE CES DERNIERS
  申请人：KARIMIAN KHASHAYAR

  公开号：WO2016098015A1

  公开（公告）日：2016-06-23

  The present invention relates to a novel process for the preparation of taxanes such as Docetaxel, a very important anticancer drug. Docetaxel 1 is a clinically well-established anti -mitotic chemotherapy medication used mainly for the treatment of breast, ovarian and non-small cell lung cancer. In this work we introduce an efficient and simple process for producing Docetaxel 1 (vide infra), including the following steps: a) hydroxyl acylation reaction of 10-DAB-III with chloroacetic acid to obtaine compound 2; b) condensation reaction of compounds 2 and 3 to obtain compound 4; c) deprotection of protecting group paramethoxy phenyl (PMP) protecting group to obtain compound 5 d) deprotection of protecting group Rl of compound 5 to prepare Docetaxel 1; wherein, Rl is, among other acetylation reagents, chloroacetyl chloride, R2 is, among other ketones and aldehydes, paramethoxy phenyl (PMP), and R3 is, among other alkanes, tert-butyl e) subjecting the crude Docetaxel to fast filtration over a short silica gel filter to obtain anhydrous Docetaxel of > 95% purity f) crystallizing the anhydrous Docetaxel of step e) to obtain pharmaceutical grade Docetaxel trihydrate. In the methods for preparation of the present invention, the protective groups used are easily removed, the purification of the intermediates is convenient, the cost of production is reduced, the steps of reaction are fewer, the yield and the purity are higher, and the processes can be scaled to commercial scale production. Another important aspect of the present invention is the preparation of pharmaceutical grade Docetaxel without resorting to chromatography.

  这项发明涉及一种新型的紫杉醇类药物如多西紫杉醇（Docetaxel）的制备过程。多西紫杉醇是一种临床上已经确立的抗肿瘤药物，主要用于治疗乳腺癌、卵巢癌和非小细胞肺癌。在这项工作中，我们介绍了一种高效简单的多西紫杉醇制备过程，包括以下步骤：a）10-DAB-III与氯乙酸的羟基酰化反应得到化合物2；b）化合物2和3的缩合反应得到化合物4；c）去保护基对甲氧基苯基（PMP）保护基的去保护反应得到化合物5；d）去除化合物5的保护基R1以制备多西紫杉醇；其中，R1是氯乙酰氯等乙酰化试剂，R2是对甲氧基苯基（PMP）等酮和醛，R3是叔丁基等烷基；e）将粗多西紫杉醇快速过滤于短硅胶过滤器上，得到纯度>95%的无水多西紫杉醇；f）结晶化步骤e）的无水多西紫杉醇，得到药用级多西紫杉醇三水合物。在本发明的制备方法中，所使用的保护基易于去除，中间体的纯化方便，生产成本降低，反应步骤较少，产率和纯度较高，并且这些过程可以扩展到商业规模生产。本发明的另一个重要方面是制备药用级多西紫杉醇而无需使用色谱法。